Amol Akhade: New Development Therapeutic Data to Watch at ASCO 2025
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:
“New Development Therapeutic Data to Watch at ASCO 2025.
From first-in-class mRNA bispecifics to next-gen radioligands, ASCO25 is shaping up to be a breakthrough year for early-phase oncology innovation.
Here are 10 exciting developments in the Developmental Therapeutics track:
1. Emi-Le (B7-H4 ADC)
A B7-H4–directed dolasynthen ADC showing early promise in triple-negative breast and other solid tumors. Targeting a previously ‘undruggable’ checkpoint.
2. LBL-024 (PD-L1/4-1BB bispecific)
A unique fusion antibody activating immune costimulation + checkpoint blockade. Being tested in platinum-naive neuroendocrine carcinoma.
3. IMA203 (PRAME TCR-T)
An autologous TCR therapy targeting PRAME – a cancer-testis antigen – in PD-1–refractory melanoma. Also part of a randomized trial.
4. BNT142 (CLDN6 × CD3 mRNA bispecific)
From BioNTech’s pipeline – this mRNA-encoded bispecific antibody engages T-cells via CD3, directed against CLDN6+ tumors.
5. GFH375 (KRAS G12D inhibitor)
First oral, selective G12D inhibitor entering human trials. A major opportunity beyond the more common G12C mutation.
6. B440 (WT1 oral vaccine)
A live Bifidobacterium-based WT1 cancer vaccine, explored in urothelial carcinoma. A new frontier in microbiome-based delivery.
7. VMT-α-NET ([²¹²Pb] radioligand)
Targeting SSTR2+ neuroendocrine tumors with alpha-emitting payloads. May offer options post-Lu177 failure.
8. IBI363 (PD-1/IL-2α-bias fusion Ab)
Enhances CD8+ T-cell function without Treg expansion – a smart take on cytokine biasing in mucosal melanoma.
9. SYNC-T (In situ vaccination)
Intratumoral therapy + systemic activation – being studied in mCRPC. A bold push for turning ‘cold’ tumors ‘hot.’
10. KRAS G12C strategies
Adagrasib + pembrolizumab and new agents like Olomorasib show how combo and next-gen inhibitors continue to evolve in NSCLC.
Takeaway:
While many of these are early-phase, they represent mechanistic innovation, novel platforms, and bold therapeutic combinations that could reshape future standards.
Which of these are you most excited about?”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023